Shares of UniQure /zigman2/quotes/203652599/composite QURE -3.95% gained 7.2% in trading on Monday after the company said an independent data safety monitoring board said there were no safety concerns in a Phase 2/3 clinical trial for its experimental Huntington's disease treatment. The board has reviewed six months of safety data for the first two patients enrolled in the randomized, double-blind study. UniQure said it expects to enroll six more patients who have been diagnosed with the rare neurodegenerative disease by mid-2021. The investigational gene therapy is called AMT-130. "While early, we remain bullish about uniQure's [Huntington's disease] gene therapy and continue to believe the program is nearly all upside from current levels," Raymond James analyst Danielle Brill wrote in a note to investors. Uniqure's stock is down 35.9% for the past year, while the broader S&P 500 /zigman2/quotes/210599714/realtime SPX +0.36% has gained 16.5%.